MIV-711 New Osteoporosis drug

MIV-711 Medivir AB is a pharmaceutical company that focuses on infectious diseases. They recently announced phase I clinical trial for a new cathepsin K inhibitor.

This new drug is designed for the treatment of bone disorders such as osteoporosis, oseoarthritis and bone meastases which are characterized by excessive bone resorption (removal of bone).

The CEO of Medivir stated, This first study of " is an important step in our effort to develop new treatment options for patients with bone related diseases. The study will provide us with crucial biomarker information reflecting both bone and cartilage turnover. Based on this data we will be able to make a fast and informed decision regarding the continued development of ...{the drug}... to the market."

What is MIV-711?

This drug is a potent and selective reversible inhibitor of cathepsin K, a protease essential for bone destruction. The drug is being developed as a new therapy for disease states where a reduction in cathepsin K activity would be advantageous.

In this human study, the drug will be administered as single ascending oral doses to healthy volunteers. This will be followed by repeated once daily doses for 7 days. The aim is to explore the safety, tolerability and pharmacokinetics. In addition effect on biomarkers relevant for bone and cartilage degradation will be followed. It will also be studied in postmenopausal women following once daily oral dosing for 14 days.

The design of the study will allow Medivir to explore how this drug affects biomarkers known to be relevant for measuring bone and cartilage turnover. It will also provide the company with valuable information regarding potential therapeutic dose levels to be used in future studies. The results from this study are expected in the first quarter of 2013.

Source: Medivir

Link to a press release about this trial: MIV-711

Go to Osteoporosis medications